A phase I study of chemoradiotherapy (cisplatin and vinorelbine) with use of involved-field conformal radiotherapy and accelerated hyperfractionation for stage III non-small cell lung cancer

A phase I study of chemoradiotherapy (cisplatin and vinorelbine) with use of involved-field conformal radiotherapy and accelerated hyperfractionation for stage III non-small cell lung cancer - A phase I study of chemoradiotherapy with 3DCRT for stage III NSCLC

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003769

Enrollment

Registered

2010-06-21

Start date

2008-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small-cell lung cancer

Interventions

cisplatin and vinorelbine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Histologicaly or cytologicaly proven NSCLC (2) Un-treated patients with IIIA/IIIB NSCLC. When radio-oncologist judged that the patients can tolerable for full dose irradiation. (3) V20 and less 35% (4) ECOG Performance status 0-1 (5) age under than 75 (6) Measurable lesion (RECIST) (7) Adequate organ function (8) Written informed consent

Exclusion criteria

Exclusion criteria: (1) With interstitial pneuminia or pulmonary fibrosis (2) Presence of other active malignancy (3) Pregnancy or lactating patients (4) A male without the intention to contraception (5) With sever cardiac diseases (6) Un-controlled DM (7) With sever infection (8) With high fiver (9) Previous treatment of thoracic irradiation (10) Others

Design outcomes

Primary

Measure	Time frame
recommended dose of radiotherapy	—

Secondary

Measure	Time frame
Toxicity, response, overall survival	—

Countries

Japan

Contacts

Public ContactNaruo Yoshimura

Graduate School of Medicine, Osaka City University Department of Respiratory Medicine

y-naruo@sc4.so-net.ne.jp06-6645-3793

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026